A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | MicrobiomeTrials← Back to trialsNCT07811297
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-01Est. Completion: 2030-09-01
Enrollment target: 138 participants Locations- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaUterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, t…
Birmingham, United StatesEst. completion Oct 31, 2027
Recruiting
Grade 1 Endometrial Endometrioid CarcinomaEndometrial Intraepithelial NeoplasiaMetabolic Comorbidities
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with…
Hershey, United StatesEst. completion May 1, 2028
Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-…
Shanghai, ChinaEst. completion Mar 30, 2028